Wednesday, July 8, 2026

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GSK Glaxo Smith clinical programs — 70 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Intelligence · Clinical Programs

GSK Glaxo Smith projects

70 ClinicalTrials.gov programs sponsored by GSK Glaxo Smith.

GSK Glaxo Smith has 70 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 2 small molecule active

    1 trial
  2. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial
  3. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial
  4. NaCl 0.9% solution

    GlaxoSmithKline

    Meningitis, Meningococcal

    phase 2 small molecule active

    1 trial
  5. NaCl solution

    GlaxoSmithKline

    Herpes Simplex

    phase 2 small molecule active

    1 trial
  6. Other: Placebo

    GlaxoSmithKline

    Menopausal and Female Climacteric States

    phase 2 small molecule completed

    1 trial
  7. Placebo for GSK5784283.

    GlaxoSmithKline

    Asthma

    phase 2 small molecule active

    1 trial
  8. Placebo to Match GSK3915393 Tablet

    GlaxoSmithKline

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial
  9. Placebo to Match GSK3965193 Tablets

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial
  10. Reblozyl 75 mg powder for solution for injection

    GlaxoSmithKline

    Myelofibrosis

    phase 2 small molecule active

    1 trial
  11. Rotarix™

    GlaxoSmithKline

    Infections, Rotavirus

    phase 2 mab completed

    1 trial
  12. SB497115

    GlaxoSmithKline

    Thrombocytopaenia

    phase 2 small molecule completed

    1 trial
  13. SB497115

    GlaxoSmithKline

    Purpura, Thrombocytopaenic, Idiopathic

    phase 2 small molecule completed

    1 trial
  14. SERETIDE Rotacaps

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial
  15. SRA-MMB-4365/219627

    GlaxoSmithKline

    Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

    phase 2 other active

    1 trial
  16. Solabegron

    GlaxoSmithKline

    Overactive Bladder

    phase 2 small molecule completed

    1 trial
  17. albiglutide

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 2 mab completed

    1 trial
  18. dabrafenib

    GlaxoSmithKline

    Solid Tumours

    phase 2 small molecule completed

    1 trial
  19. meningococcal ACWY (vaccine)

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 mab completed

    1 trial
  20. pazopanib (GW786034)

    GlaxoSmithKline

    Neoplasms, Uterine Cervix

    phase 2 small molecule completed

    1 trial
  21. pazopanib (GW786034) 400 mg

    GlaxoSmithKline

    Neoplasms, Breast

    phase 2 small molecule completed

    1 trial
  22. sterile saline solution (0.9% w/v solution of NaCl in water).

    GlaxoSmithKline

    Urinary Tract Infections

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does GSK Glaxo Smith have?

70 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.